Overall, carriers of heterozygous FANCA alterations showed an increased risk of developing MDS (OR 4.9, P < 0.001), patients with FANCG showed an increased risk of developing MDS (OR 5.9, P < 0.05) and patients carrying FANCE variants tended to show a stronger risk for development of MDS although not statistically significant (OR 4.9, P < 0.10). Here, FANCE is linked to myelodysplastic syndrome.